Donald L. Siegel, MD, PhD
Pathology and Laboratory Medicine
Accepting new patients
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider
About me
- Director, Division of Transfusion Medicine and Therapeutic Pathology, Hospital of the University of Pennsylvania
- Director, Clinical Cell and Vaccine Production Facility, Penn Medicine
- Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
My areas of clinical expertise include transfusion medicine, blood banking, apheresis, hematopoietic stem cell collection/processing, and cGMP manufacture of cellular therapies for phase I first-in-human clinical trials. My translational lab research interests are in the engineering of recombinant antibodies for development of human and canine immunotherapies.
My education and training
- Medical School: University of Pennsylvania School of Medicine
- Residency: University of Pennsylvania Health System
- Fellowship: University of Pennsylvania Health System
Spoken languages
English
English
Insurance accepted
Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.
- Aetna Advantra Cares D-SNP
- Aetna Advantra Credit Value
- Aetna Advantra Eagle HMO
- Aetna Advantra Eagle POS
- Aetna Advantra Premier Plus PPO
- Aetna Advantra Value
- Aetna Advantra Value Plus
- Aetna APCN Plus (Multi-Tier)
- Aetna Better Health Kids (CHIP) - DH Only
- Aetna Flexible Five
- Aetna Freedom Core
- Aetna Gold
- Aetna HMO
- Aetna Philly Prime
- Aetna POS
- Aetna PPO APCN
- Aetna Premier
- Aetna Premier Plus
- Aetna Savings Plus
- Aetna Signature Administrators
- Aetna Student Health Plan PPO
- Aetna Upfront Advantage
- First Health HMO
- First Health POS
- First Health PPO
- Meritain - Aramark (Other)
- Meritain - Aramark (Pennsylvania Premier Medical Plan)
- Centivo EPO
- Cigna Healthcare EPO
- Cigna Healthcare HMO
- Cigna Healthcare POS
- Cigna Healthcare PPO
- Claim Watcher (Homestead/ INDECs) Open Access
- Clover Health Choice
- Clover Health Choice Value PPO
- Clover Health Classic HMO
- Clover Health Value
- Devoted Health Choice Giveback Pennsylvania (PPO)
- Devoted Health Choice Pennsylvania (PPO)
- Devoted Health Choice Plus Pennsylvania (PPO)
- Devoted Health Core Pennsylvania (HMO)
- Devoted Health Dual Plus Pennsylvania (HMO D-SNP)
- Devoted Health Giveback Pennsylvania (HMO)
Locations
Penn Medicine hospital privileges
- Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
- Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Qualifications and experience
- Pathology, 1992
- AABB, International
- AABB Biotherapies Leadership Committee, International
- AABB Memorial Awards Committee, International
- American Society for Apheresis, National
- American Society of Hematology, National
- Clinical Applications and Standards Committee, American Society for Apheresis, National
- Department of Transfusion Medicine, National Institutes of Health, National
- Executive Committee of the Medical Advisory Board, Penn-Jersey Division of the American Red Cross, Local
- International Society for Cellular Therapy, International
- John Morgan Society, Local
- Medical Advisory Committee, Penn-Jersey Division of the American Red Cross, Local
- NIH NHLBI NITM NRSA Institution Research Training Grant (T32), National
- NIH NHLBI NITM NRSA Institution Research Training Grant (T32), National
- NIH Study Section "Selected Topics in Transfusion Medicine" (ZRG1 VH-E 50R), National
- NIH, Member, Selected Topics in Transfusion Medicine Study Section, National
- Scientific Subsection Committee, American Association of Blood Banks, National
- Society for Immunotherapy of Cancer, International
- Penn Bone Marrow Transplant and Stem Cell Transplant Program
- Penn Hematological Malignancies (Blood Cancer) Program
Treatments and conditions
Research
Publications
Bhoj, V.G., Kaminski, M., Zhao, H., Jackson, K., Montgomery, R.A., Ali, N., Mangiola, M., Spitzer, T.R., Safa, K., Pattanayak, V., Taj, R., Joy Chiu, J., Bui, T.-M., Sonnenberg, E.M., Markmann, J.F., Milone, M.C., June, C.H., Siegel, D.L., Fraietta, J.A., Gonzalez, V., Locci, M., Palmer, M., Monos, D., Hwang, W.-T .Sledge, T., Bridges, N.D., Goldstein, J.S., Odim, J., Sweet, S.C., Besharatian, B.D., Hussain, S.M., Brown, N.K., Kamoun, M., Garfall, A.L., Naji, A. Kidney transplant in two highly-sensitized candidates post-CAR T cell therapy , N Engl J Med, in press: 2026
Barber-Rotenberg, J.S., Haas, A.R., Aggarwal, C., O'Hara, M.H., Hexner, E., Pequignot, E., Dowd, E., Ndeupen, S., Thai, E., Chen, F., Oner, B.S., Czuczman, C., Gonzalez, V.E., Fraietta, J.A., Hwang, W.-T., Chew, A., Jadlowsky, J.K., Marshall, A., Shea, K.-M., Jiang, Y., Cosey, A., Ferthio, R., Plesa, G., Siegel, D.L., Young, R.M., Sheppard, N.C., Albelda, S.M., June, C.H., Tanyi, J.L. Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers , Molecular Therapy, in press: 2026
Jadlowsky, J.K., Hexner, E.O., Marshall, A., Grupp, S.A., Frey, N.V., Riley, J.L., Veloso, E., McConville, H., Rogal, W., Czuczman, C., Hwang, W.-T., Li, Y., Leskowitz, R.M., Farrelly, O., Karar, J., Christensen, S., Barber-Rotenberg, J., Gaymon, A., Aronson, N., Bernstein, W., Melenhorst, J.J., Roche, A.M., Everett, J.K., Zolnoski, S.A., McFarland, A.G., Reddy, S., Petrichenko, A., Cook, E.J., Lee, C., Gonzalez, V.E., Alexander, K., Kulikovskaya, I., Ramírez-Fernández, A., Minehart, J.C., Ruella, M., Gill, S.I., Schuster, S.J., Cohen, A.D., Garfall, A.L., Shah, P.D., Porter, D.L., Maude, S.L., Levine, B.L., Siegel, D.L., Chew, A., McKenna, S., Lledo, L., Davis, M.M, Plesa, G., Herbst, F., Stadtmauer, E.A., Tebas, P., DiNofia, A., Haas, A., Haas, N.B., Myers, R., O’Rourke, D.M., Svoboda, J., Tanyi, J.L., Aplenc, R., Jacobson, J.M., Ko, A.H., Cohen, R.B., June, C.H., Bushman, F.D., Fraietta, J.A. Long-term safety analysis in 783 patients treated with lentiviral or gammaretroviral gene-modified T-cells , Nature Medicine, doi.10.1038/s41591-024-03478-6: 2025
Bloch, E.M., Triulzi, D., Sachais, B.S., Hod, E.A., Cushing, M., Jacobs, J.W., Tobian, A.A.R., Shan, H., Leonard N. Chen, L.N., McGonigle, A.M., Tormey, C.A., Szczepiorkowski, Z.M., Siegel, D.L. The incompatible match for transfusion medicine fellowships , Transfusion, 65: 2025,246-248
Chen, G.M., Gering, D., Satulovsky, J., Datta, S., Lai, P., Karar, J., Gonzalez, V.E., Alexander, K., Chew, A., Jadlowsky, J.K., Ruella, M., Paruzzo, L., Amses, K.R., Rech, A.J., Stadtmauer, E.A., Frey, N.V., Hexner, E.O., Porter, D.L., Cohen, A.D., Gill, S.I., Garfall, A.L., Schuster, S.J., Mo, K.C., Liang, S.I., Spasic, M., Levine, B.L., Siegel, D.L., Ramírez- Fernández, A., Mackall, C.L., Bushman, F.D., Good, Z., E. John Wherry, E.J., June, C.H., Jain, A., Cabanski, C., Fraietta, J.A. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-hematologic cancer , Nature Biomedical Engineering, in press: 2025
Svoboda, J., Landsburg, D.J., Gerson, J., Nasta, S.D., Barta, S.K., Chong, E.A., Cook, M., Frey, N.V., Shea, J., Cervini, A., Marshall, A., Four, M., Davis, M.M., Jadlowski, J.K., Chew, A., Pequignot, E., Gonzalez, V., Noll, J.H., Paruzzo, L., Rojas-Levine, J., Plesa, G., Schollar, J., Siegel, D.L., Levine, B., Porter, D.L., Ghassemi, S., Ruella, M., Rech, A., Leskowitz, R.M., Fraietta, J.A., Hwang, W.-T., Hexner, E., Schuster, S.J., June, C.H. Enhanced CAR T-cell therapy for lymphoma after previous failure , New England J Med, 392: 2025,1824-1835
Bagley, S.J., Desai, A.S., Fraietta, J.A., Silverbush, D., Chafamo, D., Freeburg, N.F., Gopikrishna, G.K., Rech, A.J., Nabavizadeh, A., Bagley, L.J., Park, J., Jarocha, D., Martins, R., Sarmiento, N., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R.M., Jadlowsky, J.K., Mackey, S., Christensen, S., Oner, B.S., Plesa, G., Brennan, A., Gonzalez, V. Chen, F., Barrett, D., Colbourn, R., Nasrallah, M.P., Mourelatos, Z., Hwang, W.-T., Alanio, C., Siegel, D.L., June, C.H., Hexner, E.O., Binder, Z.A., O'Rourke, D.M. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial , Nature Medicine, doi/10.1038/s41591-025-03745-0: 2025
Ramirez-Fernández, A., Dimitri, A., Chen, F., Bartoszek, R., Chen, G., Córdoba-Espejo, L., Zhou, Y., Tang, Y.H., Lin, C.-T., Acosta, R., Scholler, J., Ghilardi, G., Porazzi, P., Pellicer, M., Profitós-Pelejà, N., Barta, S., Chew, A., Jadlowsky, J., Vanessa Gonzalez, V., Siegel, D.L., Levine, B., Roué, G., Ruella, M., Lotze, M., June, C.H., Riley, J., Fraietta, J. CCR5-targeted allogeneic gamma-delta CD19 CAR T cells for HIV-associated B cell malignancy immunotherapy , Nature Biomedical Engineering: 2025
Myers, R.M., DiNofia, A.M., Li, Y., Diorio, C., Liu, H., Wertheim, G., Fraietta, J.A., Gonzalez, V., Plesa, G., Siegel, D.L., Iannone, E., Shinehouse, L., Brogdon, J.L., Taylor, C., Jadlowsky, J.K., Hexner, E.O., Engels, B., Baniewicz, D., Callahan, C., Ruella, M., Aplenc, R., Leahy, A.B., McClory, S.E., Rheingold, S.R., Wray, L., June, C.H., Maude, S.L., Frey, N.V., Grupp, S.A. CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy , J Immunoherapy Cancer, doi:10.1136/jitc-2025-011549: 2025
Aznar, M.A., Good, C.R., Barber-Rotenberg, J.S., Agarwal, S., Wilson, W., Watts, A., Zhang, Z., Gonzales, D., Donahue, G., Hwang, W.-T., Rennels, A.K., Rech, A.J., Kuramitsu, S., Glastad, K.M., Alexander, K.A., Plesa, G., Brennan, A., Siegel, D.L., Tanyi, J., Haas, A., Drew Torigian, D., Nadolski, G., Gonzalez, V.E., Hexner, E.O., Fraietta, J.A., Jadlowsky, J.K., Young, R.M., Berger, S.L., June, C.H., O’Hara, M.H. Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer , Cell Reports Medicine, doi/10.1016/j.xcrm.2025.102301: 2025